Cryptotanshinone inhibition of mammalian target of rapamycin pathway is dependent on oestrogen receptor alpha in breast cancer

Yanhong Pan a, b, Junfeng Shi c, Wenting Ni a, Yuping Liu a, Siliang Wang a, Xu Wang a, Zhonghong Wei a, Aiyun Wang a, Wenxing Chen a, b, *, Yin Lu a, b, *

a School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China
b Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, China
c Department of Oncology, Nanjing First Hospital of Nanjing Medical University, Nanjing, China

Received: September 29, 2016; Accepted: January 23, 2017

Abstract

Cryptotanshinone (CPT) has been demonstrated to inhibit proliferation and mammalian target of rapamycin (mTOR) pathway in MCF-7 breast cancer cells. However, the same results are unable to be repeated in MDA-MB-231 cells. Given the main difference of oestrogen receptor α (ERα) between two types of breast cancer cells, it is possibly suggested that CPT inhibits mTOR pathway dependent on ERα in breast cancer. CPT could significantly inhibit cell proliferation of ERα-positive cancer cells, whereas ERα-negative cancer cells are insensitive to CPT. The molecular docking results indicated that CPT has a high affinity with ERα, and the oestrogen receptor element luciferase reporter verified CPT distinct anti-oestrogen effect. Furthermore, CPT inhibits mTOR signalling in MCF-7 cells, but not in MDA-MB-231 cells, which is independent on binding to the FKBP12 and disrupting the mTOR complex. Meanwhile, increased expression of phosphorylation AKT and insulin receptor substrate-1 (IRS1) induced by insulin-like growth factor 1 (IGF-1) was antagonized by CPT, but other molecules of IGF-1/AKT/mTOR signalling pathway such as phosphatase and tensin homolog (PTEN) and phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) were negatively affected. Finally, the MCF-7 cells transfected with shERα for silencing ERα show resistant to CPT, and p-AKT, phosphorylation of p70 S6 kinase 1 (p-S6K1) and eukaryotic initiation factor 4E binding protein 1 (4E-BP1) were partially recovered, suggesting ERα is required for CPT inhibition of mTOR signalling. Overall, CPT inhibition of mTOR is dependent on ERα in breast cancer and should be a potential anti-oestrogen agent and a natural adjuvant for application in endocrine resistance therapy.

Keywords: cryptotanshinone ● mammalian target of rapamycin ● oestrogen receptor α ● insulin receptor substrate 1 ● breast cancer

Introduction

The incidence of human breast cancer increases gradually recent decades all over the world [1]. Its pathogenic factors are related to lifestyle [2, 3], carcinogenic gene [4], medical conditions [5] and so on. However, it is well documented that the mitogenic actions of endogenous estradiol are pivotal in the initiation and progression of breast cancers [6]. Thus, oestrogen receptors become the critical target for preventing and healing the breast cancer. Oestrogen receptors (ERs) are members of the nuclear receptor super family, mediating the pleiotropic effects of the steroid hormone oestrogen in a diverse range of developmental and physiological processes [6]. Most importantly, they have also been pathologically associated with an increased risk for the initiation and development of breast cancer [6]. Approximately 70%–75% of patients with breast cancer have been demonstrated to be oestrogen receptor alpha positive (ERα+), indicating that ERα plays an important role in breast cancer [7, 8].

Oestrogen receptor alpha (ERα), a member of the nuclear receptor family of transcription regulators, mediates cell growth [6], metastasis [9], resistance to apoptosis [10] and immunosurveillance [11]. ERα directly binding with 17β-estradiol (E2) induces gene
transcription through activating oestrogen response element (ERE) and contributes to the initiation, development and metastasis of breast, uterine and ovary cancer [12]. Furthermore, it is also activated by the epidermal growth factor-activated extracellular kinase pathway and other signal transduction pathways such as insulin-like growth factor (IGF-1) [8]. ERα has been an unavoidable target for curing most of woman cancers related to oestrogen, especially the breast cancer [8].

Current available endocrine therapies for ER-positive breast cancers mainly include the selective ER modulators (SERMs, e.g. tamoxifen and fulvestrant) which exert dual agonistic or antagonistic effects on ER transcription, and aromatase inhibitors (e.g. letrozole) which inhibit oestrogen biosynthesis in postmenopausal patients [13]. Additionally, gonadotropin-releasing hormone analogues, suppressing oestrogen biosynthesis in premenopausal patients, are also becoming an important type of anticancer drugs [13, 14]. Among them, SERMs were used most frequently at present in clinic. Tamoxifen, a typical SERM has been used as a chemopreventive agent for hormone-dependent breast cancer [14]. However, the long-term therapy with tamoxifen should lead to a high risk for cancer and the acquired resistance to tamoxifen [15, 16]. Thus, discovery of better SERMs without carcinogenic risk and resistance is considerably significant.

CPT is a natural phenanthraquinone compound from *Salvia miltiorrhiza Bunge* with anti-inflammatory [17], bacterium [18], antidiabetes [19], antitumour [20, 21] and more [22]. Particularly, its antitumour action and molecular mechanisms initially attract much concern [21]. In previous study, we have found that inhibition of mTOR pathway mediates CPT inducing cancer cell arrested in G0 phase, leading to cell death in most of cancer cell lines [20]. However, when CPT was added into breast cancer cells, a significant inhibition was observed in MCF-7 but not in MDA-MB-231 cells, as well as the same change in mTOR signalling. Considering the major difference between two cancer cell lines is ERα that one expressed but another did not, we thought it may be a key factor mediating CPT inhibition of mTOR pathway.

In this article, we firstly demonstrated that CPT indicated a significant inhibitory effect on cell proliferation and mTOR signalling in MCF-7 cells, while did not in MDA-MB-231. Then, it was found that CPT could bind to ERα with inhibition of ER activity. Finally, its role on crosstalk between ERα and IGF-1/PI3K/mTOR pathway was confirmed, convincing us that CPT should be a potential agent for prospective application in a tamoxifen-resistant breast cancer.

**Materials and methods**

**Reagents**

CPT (98% purity) was purchased from Xi’an Hao-Xuan Bio-Tech Co., Ltd. CPT was dissolved in 100% ethanol to prepare the stock solutions (20 mmol/l), aliquoted and stored at –20°C. Dulbecco’s Modified Eagle Medium (DMEM) and RPMI1640 medium were purchased from Gibco (Grand Island, NY, USA). Foetal bovine serum (FBS) was from Hyclone (Logan, UT, USA) and trypsin from Invitrogen (Grand Island, NY, USA). MTS and tamoxifen were from Sigma-Aldrich (St. Louis, MO, USA). HitHunter™ Estrogen Assay Kit was from DiscoverX corporation (Fremont, CA, USA). ERE reporter assay kit and attractene transfection reagent were from Qiagen (Germantown, MD, USA). Luciferase assay system was from Promega (Madison, WI, USA). Insulin-like growth factor (IGF-1) (PeproTech, Rocky Hill, NJ, USA) was rehydrated in 0.1 M acetic acid to prepare a stock solution (10 g/ml), aliquoted and stored at –80°C. The following antibodies were used: 4E-BP1 (GeneTex, Irvine, CA, USA), phospho-4E-BP1 (Thr37/46), 4E-BP1, cyclin D1, Rb, PI3K (p85), PI3K (p110), PTEN, phospho-PTEN (Ser380) (Santa Cruz, Dallas, TX, USA); IRS1, phospho-IRS1 (Ser636/639), phospho-mTOR (Ser2448), mTOR, raptor, phospho-raptor (Ser792), rictor, mLST8 (Cell Signaling, Boston, MA, USA).

**Cell lines and cell culture**

MCF-7, T47D, MDA-MB-231 and MDA-MB-435 cells were from institute of biochemistry and cell biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences. These cells were cultured in DMEM with 10% FBS and grown in a humidified atmosphere, containing 5% CO₂ at 37°C. For experiments where cells were deprived of serum, cell monolayers were washed with phosphate-buffered saline (PBS) and incubated in the serum-free DMEM. MCF-7/ADR cells (MCF-7 cells resistant to Adriamycin) from Nanjing First Hospital of Nanjing Medical University were cultured in RPMI1640 medium with 10% FBS and 0.25 µg/ml Adriamycin. When for use, the medium was replaced with fresh RPMI1640 containing 10% FBS.

**Cell proliferation assay**

Cancer cells dispersed evenly in appropriate medium were seeded in a 96-well plate with a density of 1 × 10⁴ cells/well. Next day, cells were treated with various concentration of the tested compounds for the indicated time with 6 replicates of each treatment. After incubation, each well was added 20 µl of MTS [3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] reagent and incubated for 3 hrs. Cell viability was determined by measuring the optical density at 490 nm using a BioTeck microplate reader (BioTeck, Sunnyvale, CA, USA).

**Molecular docking assay**

The three-dimensional structure of CPT, 17β-estradiol and tamoxifen was retrieved from PubChem database (https://pubchem.ncbi.nlm.nih.gov/). Meanwhile, the structure of ERα (Protein Data Bank (PDB) ID: 1A52 with resolution of 2.80 Å) was retrieved from the Research Collaborator for Structural Bioinformatics PDB (Anonymous, www.rcsb.org). The docking behaviour between the three compounds and ERα were evaluated by Discovery Studio (DS) 3.5 using the CDOCKER Protocol under the protein–ligand interaction section after preparing protein and ligands. The poses were scored by CDOCKER energy and CDOCKER interaction energy, the best among 10 binding poses was finally showed [23].

**Oestrogen receptor binding assay**

HitHunter™ Estrogen Assay Kit was used to confirm the competitive binding of compounds to oestrogen receptor. Oestrogen analogues
the concentration of oestrogen analogues bound to the oestrogen receptor. The amount of free ED conjugate in the assay is proportional to hydrolyses luminescent substrate for EFC detection by a microplate.说着 protein fragment, to form active enzyme, which subsequently and tamoxifen (1 \( \text{mol/l} \)) was administrated orally once a day starting from the day after injection of MCF-7 cells. And the length and width of the tumour was measured every 2 days. The volume of the tumour was calculated from the formula length \( \times \) width\(^2\) \( \times \) 0.52 as the described. Approximately 4 weeks later, solid tumour was carefully excised from the outer of mice and none-tumour tissues were separated clearly. Then, it is fixed in formalin for further analysis. Another experiment in MDA-MB-231 cells was repeated according to the same method.

**Western blotting**

Cells were lysed in RIPA buffer. Protein concentration was determined by bichinonic acid assay with bovine serum albumin as standard (Pierce, Rockford, IL, USA). Aliquots of each cytosolic extract containing 20 \( \mu \text{g} \) of protein were separated by SDS-PAGE (12%), transferred to polyvinylidene difluoride membranes (Millipore, Bedford, MA, USA) by electroblotting. Membranes were incubated with 5% non-fat milk solution containing 0.05% Tween-20 for blocking non-specific binding and were incubated with primary antibodies overnight at 4°C cold room, then with appropriate secondary antibodies conjugated to horseradish peroxidase. Immunoreactive bands were visualized by enhanced chemiluminescence reagent.

**Co-immunoprecipitation**

The immunoprecipitation assay was completed as described previously [24]. In brief, MCF-7 cells were seeded in 100-mm dishes in appropriate medium containing 10% FBS for 2 days, then starved in serum-free DMEM for 24 hrs. Standard protocols including exposure to CPT (5 \( \mu \text{mol/l} \) & 10 \( \mu \text{mol/l} \)) for 2 hrs before or after stimulation with 10 ng/ml IGF-1 for 1 hr were executed. For the mTOR co-immunoprecipitation experiments, cells were washed once in ice-cold PBS and lysed in ice-cold 1 \( \times \) Chaps buffer; 500 \( \mu \text{l} \) of cell lysates was incubated overnight at 4°C with 1 \( \mu \text{g} \) of goat anti-mTOR antibody and 30 \( \mu \text{g} \) of protein A/G plus agarose. Immunoprecipitates were washed with 1 \( \times \) Chaps buffer four times and twice with mTOR immunoprecipitation wash buffer. Samples were subjected to SDS-PAGE as described above.

**Plasmids and transient transfection**

The ER\( \alpha \) shRNA plasmid was a gift from Dr. Yujie Sun, Department of Cell Biology, Nanjing Medical University (Nanjing, China). For silencing ER\( \alpha \), oligonucleotide as follow: sense 50-GATCCCCGCTACTGTTTGCTCC TAACTTCAAGAGAGTTGGAACGAAACAGTAGCTTTTGGGAAA-30; antisense 50-AGCTTTTCCAAAGAGGTACCTGTTTCGTCCTTAATCTGTTGAAAG-30; annealed and transformed into MCF-7 cells. Then, 6 hrs after transfection, culture medium was changed to normal medium. The pGC-control-shRNA was used as a negative control [25].

**Statistical analysis**

The quantitative data were analysed by one-way analysis of variance (ANOVA) followed by post hoc Dunnett’s t-test for multiple comparisons. The significant difference was confirmed with \( P < 0.05 \).

**Results**

**ER\( \alpha \)-positive, but not ER\( \alpha \)-negative breast cancer cells are sensitive to CPT in vitro**

Many types of cancer cells (e.g. Rh30, DU145) are sensitive to CPT [20]. However, in breast cancer cells, we found that proliferation of MCF-7 cells was significantly inhibited by CPT with IC\( _{50} \) of 8.58 \( \mu \text{mol/l} \), while MDA-MB-231 cells not with IC\( _{50} \) far more than 40 \( \mu \text{mol/l} \) (Fig. 1A and B). In addition, the number of viable MCF-7 cells is obviously less than that of MDA-MB-231 cells after treatment.
of 20 μmol/l CPT for 48 hrs (Fig. 1C). The data clued a fact in which ERα may be involved as MCF-7 is an ERα-positive cell line and MDA-MB-231 an ERα-negative cell line. To further confirm it, T47D and MDA-MB-435 cells were also used for cell proliferation assay. The same results were observed. As shown in Figure 1A, the viable curve of T47D cancer cells is extremely similar with that of MCF-7 cells, but distinctly different with that of MDA-MB-231 and MDA-MB-435 cells, as well as the IC50, indicating that the breast cancer cells with expression of ERα is more sensitive to CPT than those without expression of ERα. Thus, CPT inhibiting breast cancer cells is possibly dependent on ERα.

**CPT inhibits ERα-positive breast cancer growth in vivo**

As the difference was found in vitro in different breast cancer cells, we needed to understand whether the same outcome would be duplicated in mice. So the xenograft tumour model in female BALB/c nude mice was established, respectively, using MCF-7 and MDA-MB-231 cancer cells. The results show that the mean volume of solid tumour in mice transplanted with MCF-7 cells and treated with CPT for 22 days was significantly smaller than that of control group (Fig. 2A, C), while no distinct difference was calculated for tumour volume between CPT-treated and control mice transplanted with MDA-MB-231 cells (Fig. 2B, D). The in vivo data also suggest that ERα is required for CPT inhibition of breast cancer.

**CPT inhibits mTOR signal pathway in ERα-positive breast cancer cells**

Besides the different cell proliferation in vitro and cell growth in vivo, the related proteins of mTOR pathway were also found to express differently in two types of breast cancer cells. At the presence of IGF-1 induction, the mTOR pathway was activated, but the expression of phosphorylation mTOR(2448) was down-regulated in a concentration-dependent manner in MCF-7 cells under the treatment of CPT. The phosphorylation of S6K1, one of the direct downstream, was completely inhibited with no band stained at ≥5 μmol/l CPT, and the band of 4E-BP1 shifts obviously from position of γ to α (Fig. 3A), indicating mTOR signalling was inhibited. Further statistical analysis on the grey value of p-mTOR and p-S6K1 bands also confirmed the significant difference between IGF-1 and CPT treatment (Fig. 3B and C). However, the same results were not observed in MDA-MB-231 cells with no distinct change occurred in expression of p-mTOR.
p-S6K1 and 4E-BP1 (Fig. 3B). The above data also suggest ERα possibly plays a critical role in CPT inhibition of mTOR pathway in breast cancer cells.

CPT binds oestrogen receptor

Given the significance of ERα in CPT inhibition of breast cancer cell, it is necessary to know the relationship between CPT and the ERα. As shown in Figure 4A, CPT has a similar structure nucleus with 17β-estradiol in chemical, suggesting CPT’s oestrogen or anti-oestrogen effect. Then, we used molecular docking software to understand the possibility of CPT binding oestrogen receptor. As shown in Table 1, the result of computer aided design shows that the CDOCKER energy of CPT binding ERα (−8.231) is near 17β-estradiol (−10.300) but approximately half of tamoxifen (−20.271), as well as the CDOCKER interaction energy, cluing high affinity of CPT with ERα. The representative binding figure was illustrated in detail in Figure 4B. All of the above-mentioned data draw a conclusion that CPT is an oestrogen-like compound. Subsequently, we used HitHunter™ Estrogen Assay Kit to judge the affinity of CPT with oestrogen receptor. The data in Figure 4C indicate that CPT could obviously bind to the oestrogen receptor with its affinity weaker than 17β-estradiol and half of tamoxifen as the EC50 of CPT, 17β-estradiol and tamoxifen binding ER is, respectively, about 9.675 nmol/l, 4.352 nmol/l and 2.311 nmol/l. Furthermore, E2-element (ERE)-luciferase reporter gene assay indicates that compared with the control (CPT: 0 μmol/l), CPT no less than 5 μmol/l exerts significant inhibition on ERE with IC50 of 10.65 μmol/l (Figure 4D), suggesting its strong anti-oestrogen action.

CPT inhibits mTOR signalling independent of disrupting mTOR complex in breast cancer

To understand how CPT inhibits mTOR in MCF-7 cells, we firstly repeated the procedure of molecular docking and no evidence was attained for confirmation of CPT binding to FKBP12, the function domain of mTOR, clarifying that CPT is an unlike-rapamycin mTOR signalling inhibitor (data not shown). Then, the mTOR complex was focused as many compounds have been demonstrated to show...
inhibitory activity on mTOR by disrupting mTOR complex [24]. mTOR complex comprises mTORC1 which mainly includes mTOR, mLST8 and raptor and directly regulates S6K1 and 4E-BP1, and mTORC2 which is composed of mTOR, mLST8 and rictor and controls actin organization [26]. mTOR was immunoprecipitated from IGF-stimulated and CPT-treated MCF-7 cells, followed by immunoblotting with antibodies to mTOR, raptor, rictor and mLST8, respectively. As seen in Figure 5A, expression of raptor, rictor and mLST8 after mTOR was immunoprecipitated in MCF-7 cells treated by CPT keeps stable, meaning CPT does not disrupt the mTORC1 and mTORC2 complex. Additionally, raptor was also justified to be directly phosphorylated by AMP-activated protein kinase (AMPK) to result in mTORC1 disruption [27]. In Figure 5B, expression of p-raptor and total raptor is unaltered, indicating that direct phosphorylation of raptor was negated for CPT inhibition of mTORC1 in MCF-7 cells. Taken together, disruption of mTOR complex is not involved in CPT suppression of mTOR.

**CPT inhibits ERα-mediated IGF-1/mTOR pathway in ERα-positive breast cancer**

As CPT inhibition of mTOR pathway is independent on affecting the mTOR complex in breast cancer cells, it may be due to interference of mTOR upstream. IGF-1/P13K/AKT is an important upstream directly regulating mTOR and controlling cell proliferation. Compared with normal cells, this pathway is obviously activated and many phosphorylation proteins are highly expressed in most of cancer cells [28]. Most importantly, this signal transduction pathway is also regulated by ER. As indicated in Figure 7, there is a crosstalk between IGF-1/mTOR pathway and ER signalling in endocrine-resistant breast cancer. Oestrogen (E2)-liganded ER activates E2-regulated genes in classical pathway, but following long-term endocrine therapy, resistance can develop with bidirectional crosstalk between ER and growth factor receptors [8, 14].

As mentioned, the serum-free starved MCF-7 breast cancer cells were induced by 10 ng/ml IGF-1 and p-AKT(T308) and p-AKT(S473) expressed more than before. CPT indicated a significant inhibition on these two phosphorylation AKT proteins, but not on PI3K(p85), PI3K(p110) and p-PTEN (Fig. 6A). Additionally, IRS1, initially integrating signalling from insulin-like growth factor receptor-1 receptor (IGF-1R) and then suppressing IRS-1/AKT signalling cascade in ER+ MCF-7 cells [29], was dephosphorylated in further outcome (Fig. 6A). Compared with IGF-1 group, the statistic difference of three phosphorylated proteins with obvious change is significant ($P < 0.01$) (Fig. 6B). Thus, it is concluded that CPT inhibition of AKT-mTOR is contributed to CPT binding to ERα and inhibiting ERα-mediated IRS1/AKT signalling. To further demonstrate ERα’s action on CPT inhibition of mTOR, shRNA were used to silence ERα in MCF-7 cells. The cell proliferation assay showed
that shERα MCF-7 cells were less sensitive to CPT than shRNA MCF-7 cells (Fig. 6C). Meanwhile, compared with shRNA MCF-7 cells, p-AKT(T308) and p-AKT(S473) were partially reversed in shERα MCF-7 cells, as well as the p-S6K1 and 4E-BP1, although no significant change in p-IRS1 was detected (Fig. 6D and E).

In a word, ERα mediates CPT inhibition of IGF-1/AKT/mTOR pathway.

As mentioned above, as CPT could block ERα-mediated IGF-1/ AKT/mTOR pathway, it needs to be clarified whether CPT could inhibit tamoxifen-resistant breast cancer. So we used MCF-7/ADR cancer cells (with the acquired multi-drug resistance) specially resistant to adriamycin but also to tamoxifen to justify the deduction. As seen in Figure S1, the inhibitory effect on the MCF-7/ADR cancer cells was undetected by tamoxifen (Fig. S1A), but detected significantly by CPT (Fig. S1B). Meanwhile, CPT combined with tamoxifen exerts synergic effect on MCF-7/ADR cells (Fig. S1C). Taken together, the above results conclude that CPT exhibits an inhibition on MCF-7/ADR cells, which is related to ERα-mediated IGF-1/AKT/mTOR pathway.

Table 1 The molecular docking result of compounds with oestrogen receptor α

| Compound        | CDOCKER energy* | CDOCKER interaction energy* |
|-----------------|-----------------|----------------------------|
| 17β-estradiol   | −10.300         | −48.793                    |
| Cryptotanshinone| −8.231          | −44.603                    |
| Tamoxifen       | −20.271         | −55.697                    |

*Less energy, more stable.
**Fig. 5** CPT does not disrupting mTOR complex in breast cancer cells. Serum-starved MCF-7 cells were pretreated with CPT (0–20 μmol/l) for 2 hrs and then stimulated with or without IGF-1 (10 ng/ml) for 1 hr. Then, the cell lysates were subjected to immunoprecipitation with antibody to mTOR plus protein A/G agarose, and immunoblotting with antibodies to mTOR, raptor, rictor and mLST8 (A), or to Western blotting analysis for the indicated antibody (B).

**Fig. 6** CPT inhibits ERα-mediated IGF-1/mTOR pathway in ERα-positive breast cancer. (A) Serum-starved MCF-7 cells were pretreated with CPT (0–10 μmol/l) for 2 hrs and then stimulated with or without IGF-1 (10 ng/ml) for 1 hr. Then, the cell lysates were subjected to Western blotting analysis for the indicated antibody. (B) Quantitation of grey value of bands with significant changes from (A). Versus IGF-1, a indicates \( P < 0.01 \). (C) Cell proliferation assay was executed in MCF-7 with shRNA and ERα-silenced MCF-7 cells with shERα, the cell viability was calculated upon the absorbance measured by BioTek microplate reader. (D) Serum-starved MCF-7 cells with shRNA and ERα-silenced MCF-7 cells with shERα were pretreated with the indicated concentration of CPT for 2 hrs and then stimulated with or without IGF-1 (10 ng/ml) for 1 hr. Then, the cell lysates were subjected to Western blotting analysis for the indicated antibody. (E) Quantitation of grey value of bands with significant changes from (D). Versus IGF-1, a indicates \( P < 0.01 \).
Discussion

The PI3K/AKT/mTOR pathway plays a key role in multiple cellular processes including proliferation, growth and survival [30, 31]. The PI3K signalling proteins are activated not only in response to growth factor receptor tyrosine kinases (RTKs) and G-protein-coupled receptor, also by the insulin receptor tyrosine kinase (InsR) and the related insulin-like growth factor 1 receptor (IGF-1R) [32]. Meanwhile, PI3K could activate downstream signalling components such as phosphoinositide-dependent kinase 1 (PDK1) and AKT. Activated AKT stimulates mTORC1 complex critically controlling cellular growth and protein synthesis through negative regulation of the tumour sclerosis (TSC) (Fig. 7). The enzymatic activity of PI3K is also antagonized by the PTEN, a protein that catalyses the dephosphorylation of PIP3 [31, 32].

In breast cancer, PI3K/AKT/mTOR signalling pathway is generally activated [33], and pathway activation promotes tumour growth and progression [34]. And more importantly, oestrogen receptor could activate PI3K/AKT/mTOR signalling pathway [35]. The ER promotes the transcription of several genes encoding upstream proteins of PI3K/AKT/mTOR pathway such as receptor ligands, receptor tyrosine kinases. Particularly, oestrogen stimulation activates PI3K signalling through IGF-1R. This was shown to increase p-AKT levels and the interaction between p85 PI3K and the IGF-1R effector IRS1 [36].

In this study, CPT could inhibit ER+ MCF-7 cells with simultaneous suppression of IGF-1-induced activated mTOR signalling, whereas ER-negative MDA-MB-231 cells is insensitive to CPT, indicating ER probably is involved. Then, direct binding to mTOR and affecting the mTOR complex was demonstrated to be excluded from inhibition of mTOR. Both clued upstream of mTOR, IGF-1/PI3K/AKT signalling is the most important regulator. Upon the previous research, CPT could protect primary cortical neurons from glutamate-induced neurotoxicity through the activation of PI3K/Akt pathway [37], but inhibit macrophage migration through inhibition of PI3K activation with consequent reduction in phosphorylation of Akt and ERK1/2 [38]. In addition, CPT exerts inhibition on mTOR with simultaneous activation of AKT in Rh30 and DU145 cancer cells [20]. All of these suggested CPT affecting PI3K/AKT is associated with cell types and other unknown factors. Here, that CPT indicated significant inhibition on both phosphorylated sites, S473 and T308 of AKT in MCF-7 breast cancer cells, is not related to interference of PTEN, PI3K(p85) and PI3K(p110), but due to dephosphorylation of IRS1. Given the ERα regulation in IGF-1 induced PI3K/AKT/mTOR pathway and the above results, it is clearly supposed that ERα is required for CPT inhibition of mTOR in breast cancer. The subsequent results justified that inhibition of ERα-mediated IGF-1/AKT/mTOR signalling contributes to CPT’s inhibitory effect on ERα-positive breast cancer cells by the data that compared with sh-RNA control, sh-ERα MCF-7 cells shows a little bit of resistance to CPT as the p-S6K1 and 4E-BP1 was partially reversed with increased expression of p-AKT(S473) and p-AKT(T308).

Clinical endocrine therapy has ever been considered an optimal method for oestrogen receptor-positive (ER+) breast cancer and also produced a distinct improvement in early breast cancer [39]. However, not all breast cancer patients with ER+ attain efficacy from endocrine therapy in advanced breast cancer, and many probably encounter either no initial response, or more experience eventual disease progression despite an initial response [8, 15]. Upon disease progression, other therapies including chemotherapy, mTOR inhibitors and aromatase inhibitors would be considered [40]. It has been found in clinic that long-term tamoxifen therapy could cause an acquired resistance for breast cancer [16]. And this is probably because of mutation or loss of ER over time, down-regulation of ER co-activators, post-translational modified ER or increased growth factor receptor signalling pathway (e.g. IGF-1R) [16].

Recently, much progress has been achieved in the molecular biology of acquired endocrine resistance, including adaptive crosstalk between ER and peptide growth factor receptor pathways such as epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor 2 (HER2), IGF-1 (Fig. 7) [8]. Actually, in ER+ breast cancer, IGF-1/AKT/mTOR signalling pathway interacting with oestrogen receptor (ER) signalling becomes more complicated and interdependent with acquired endocrine resistance (Fig. 7) [14]. And the direct or indirect interaction occurred at multiple nodes within each pathway between the PI3K/AKT/mTOR pathway and the ER pathway. Targeting mTOR signalling combined with endocrine therapy may improve breast cancer treatment [14].

Given that MCF-7 is a type of breast cancer cells expressing ERα but without expression of HER2 [41], the cross-talk mediating the acquired endocrine resistance was contributed to IGF-1-induced mTOR pathway. Our results also indicated that CPT-like tamoxifen has a competitive inhibition on ERα and should be a potential anthormone agent for breast cancer. This is consistent with the results that ER mediates CPT inhibition of breast cancer cells [42]. However, CPT could inhibit Akt whose high expression of phosphorylation induced by IGF-1 was antagonized distinctly in MCF-7 cells, which is just contrary to CPT activation of AKT in non-breast cancer cells such as...
RH30, DU145 [20]. Until now, we did not have a proof to explain why CPT increases p-AKT in non-breast cancer cells, but we thought that deactivation of AKT is related to inhibit ERα in breast cancer cells. Moreover, overexpression of IRS1 has also been linked to anti-oestrogen resistance and hormone independence in breast cancer [43]. Thus, CPT’s indirect dephosphorylation of IRS1 is benefit for endocrine-resistant therapy. Collectively, combined with the results of CPT inhibition of resistant MCF-7/ADR cells, we thought CPT should be an adjuvant agent for endocrine resistance therapy.

However, the mechanisms of inducing resistance are too complicated in breast cancer to explain it by one way. Recent studies reported that acyl-CoA synthetase 4 (ACSL4) also plays a mediated role in occurrence of tamoxifen resistance via interrupting mTOR signal pathway in breast cancer [44]. ACSL4 expresses high in ERα-negative MDA-MB-231, but negative in ERα-positive MCF-7 breast cancer, indicating its inverse relation between ERα and ACSL4 [45]. ACSL4 was also regarded as a biomarker for hormone resistance in human breast cancer [46], and as an mTOR and ERα regulator to restore tumour hormone dependence in tumours with poor prognosis, showing that inhibition of activity of ACSL4 produces a reduction in the expression of the mTOR signalling and restores the sensitivity to tamoxifen [44]. Thus, whether or how CPT should reverse the resistance via inhibiting ACSL4-mediated mTOR in breast cancer needs to be elucidated in the future work.

Overall, CPT is a natural anti-oestrogen agent and could inhibit ERα-mediated IGF-1/AKT/mTOR pathway to increase the sensitivity of the ERα-positive resistant breast cancer cells.

Acknowledgements

This work was supported in part by National Natural Science Foundation of China (81672648, W. Chen; 81673725, Y. Lu; 81573859, A. Wang; 81502623, J. Shi), Natural Science Foundation of Jiangsu Province (BK2012854, W. Chen), and a project of the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), Qing Lan Project of Jiangsu and a preliminary foundation of NJUCM (13XYZ24).

Conflict of interest

The authors confirm that there are no conflict of interests.

Supporting information

Additional Supporting Information may be found online in the supporting information tab for this article:

Figure S1 CPT inhibits proliferation of MCF-7/ADR cells in vitro. Human breast cancer cells MCF-7/ADR (multi-drug resistance to Adriamycin and tamoxifen) were seeded in 96-well plates with a density of $1 \times 10^5$ cells/well, then respectively treated with (A) tamoxifen (0–20 μmol/l), (B) CPT (0–40 μmol/l) and (C) CPT plus with tamoxifen for 24 hrs, 48 hrs and 72 hrs with 6 replicates of each treatment. Cell viability was evaluated by MTS reagent using a BioTek microplate reader for absorbance.

References

1. McGuire A, Brown JA, Malone C, et al. Effects of age on the detection and management of breast cancer. Cancers. 2015; 7: 908–29.
2. Brody JG, Rudel RA, Michels KB, et al. Environmental pollutants, diet, physical activity, body size, and breast cancer: where do we stand in research to identify opportunities for prevention? Cancer. 2007; 109: 2627–34.
3. Cancer Kaiser J. Cholesterol forges link between obesity and breast cancer. Science. 2013; 342: 1028.
4. Gage M, Wattendorf D, Henry LR. Translational advances regarding hereditary breast cancer syndromes. J Surg Oncol. 2012; 105: 444–51.
5. Anothaisintawee T, Wirathukpan C, Lerdstithichai P, et al. Risk factors of breast cancer: a systematic review and meta-analysis. Asia Pac J Public Health. 2013; 25: 368–87.
6. Deroo BJ, Korach KS. Estrogen receptors and human disease. J Clin Investig. 2006; 116: 561–70.
7. Cleator SJ, Ahamed E, Coombes RC, et al. A 2009 update on the treatment of patients with hormone receptor-positive breast cancer. Clin Breast Cancer. 2009; 9: S6–17.
8. Johnston SR. New strategies in estrogen receptor-positive breast cancer. Clin Cancer Res. 2010; 16: 1979–87.
9. Kang HJ, Lee MH, Kang HL, et al. Differential regulation of estrogen receptor alpha expression in breast cancer cells by metastasis-associated protein 1. Cancer Res. 2014; 74: 1484–94.
10. Sayeed A, Konduri SD, Liu W, et al. Estrogen receptor alpha inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis. Cancer Res. 2007; 67: 7746–55.
11. Jiang X, Shapiro DJ. The immune system and inflammation in breast cancer. Mol Cell Endocrinol. 2014; 382: 673–82.
12. Tocalco-Cruz AC, Ramirez-Jaquin JO. Mechanisms that Increase Stability of Estrogen Receptor Alpha in Breast Cancer. Clin Breast Cancer. 2017; 17: 1–10.
13. Orlando L, Schiavone P, Fedele P, et al. Molecularly targeted endocrine therapies for breast cancer. Cancer Treat Rev. 2010; 36: S67–71.
14. Ciruelos Gil EM. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer. Cancer Treat Rev. 2014; 40: 862–71.
15. Ring A, Dowssett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer. 2004; 11: 643–58.
16. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011; 62: 233–47.
17. Tang S, Shen XY, Huang HQ, et al. Cryptotanshinone suppressed inflammatory cytokines secretion in RAW264.7 macrophages through inhibition of the NF-kappaB and MAPK signaling pathways. Inflammation. 2011; 34: 111–8.
18. Lee DS, Lee SH, Noh JG, et al. Antibacterial activities of cryptotanshinone and dihydrotanshinone I from a medicinal herb, Salvia miltiorrhiza Bunge. Biosci Biotechnol Biochem. 1999; 63: 2236–9.
19. Kim EJ, Jung SN, Son KH, et al. Antidiabetes and antiobesity effect of
cryptotanshinone via activation of AMP-activated protein kinase. *Mol Pharmacol.* 2007; 72: 62–72.

20. Chen W, Luo Y, Liu L, *et al.* Cryptotanshinone inhibits cancer cell proliferation by suppressing Mammalian target of rapamycin-mediated cyclin D1 expression and Rb phosphorylation. *Cancer Prev Res (Phila).* 2010; 3: 1015–25.

21. Shin DS, Kim HN, Shin KD, *et al.* Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells. *Cancer Res.* 2009; 69: 193–202.

22. Chen W, Lu Y, Chen G, *et al.* Molecular evidence of cryptotanshinone for treatment and prevention of human cancer. *Anti-Cancer Agents Med Chem.* 2013; 13: 979–87.

23. Cerqueira NM, Bras NF, Fernandes PA, *et al.* MADAMM: a multitaged docking with an automated molecular modeling protocol. *Proteins.* 2009; 74: 192–206.

24. Bevers CS, Chen L, Liu L, *et al.* Curcumin disrupts the Mammalian target of rapamycin-raptor complex. *Cancer Res.* 2009; 69: 1000–8.

25. Shi JF, Li XJ, Si XX, *et al.* ERalpha positively regulated DNMT1 expression by binding to the gene promoter region in human breast cancer MCF-7 cells. *Biochem Biophys Res Commun.* 2012; 427: 47–53.

26. Gough NR. Focus issue: TOR signaling, a tale of two complexes. *Sci Signal.* 2012; 5: eg4.

27. Gwinn DM, Shackelford DB, Egan DF, *et al.* AMPK phosphorylation of raptor mediates a metabolic checkpoint. *Mol Cell.* 2008; 30: 214–26.

28. Polivka J Jr, Janku F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. *Pharmacol Ther.* 2014; 142: 164–75.

29. Cesaroni G, Edupuganti OP, Chen CP, *et al.* Insulin receptor substrate 1 knockdown in human MCF7 ER+ breast cancer cells by nuclease-resistant IRS1 siRNA conjugated to a disulfide-bridged D-peptide analogue of insulin-like growth factor 1. *Bioconjug Chem.* 2007; 18: 1831–40.

30. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. *J Clin Oncol.* 2010; 28: 1075–83.

31. Liu P, Cheng H, Roberts TM, *et al.* Targeting the phosphoinositide 3-kinase pathway in cancer. *Nat Rev Drug Discovery.* 2009; 8: 627–44.

32. Adams JR, Schachter NF, Liu JC, *et al.* Elevated PI3K signaling drives multiple breast cancer subtypes. *Oncotarget.* 2011; 2: 435–47.

33. Miller TW, Rexer BN, Garrett JT, *et al.* Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. *Breast Cancer Res.* 2011; 13: 224.

34. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. *Nat Rev Cancer.* 2009; 9: 550–62.

35. Simoncini T, Hafezi-Moghadam A, Brazil DP, *et al.* Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol 3-kinase. *Nature.* 2000; 407: 538–41.

36. Miller TW, Perez-Torres M, Narasanna A, *et al.* Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. *Cancer Res.* 2009; 69: 4192–201.

37. Zhang F, Zheng W, Pi R, *et al.* Cryptotanshinone protects primary rat cortical neurons from glutamate-induced neurotoxicity via the activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. *Exp Brain Res.* 2009; 193: 109–18.

38. Don MJ, Liao JF, Lin LY, *et al.* Cryptotanshinone inhibits chemotactic migration in macrophages through negative regulation of the PI3K signaling pathway. *Br J Pharmacol.* 2007; 151: 638–46.

39. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. *Lancet.* 1998; 351: 1451–67.

40. Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. *Nat Rev Cancer.* 2002; 2: 101–12.

41. Monks A, Scudiero D, Skehan P, *et al.* Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. *J Natl Cancer Inst.* 1991; 83: 757–66.

42. Li S, Wang H, Hong L, *et al.* Cryptotanshinone inhibits breast cancer cell growth by suppressing estrogen receptor signaling. *Cancer Biol Ther.* 2015; 16: 176–84.

43. Surma E, Burgaud JL. Overexpression of insulin receptor substrate 1 (IRS-1) in the human breast cancer cell line MCF-7 induces loss of estrogen requirements for growth and transformation. *Clin Cancer Res.* 1995; 1: 1429–36.

44. Orlando UD, Castillo AF, Dattilo MA, *et al.* Acyl-CoA synthetase-4, a new regulator of mTOR and a potential therapeutic target for enhanced estrogen receptor function in receptor-positive and -negative breast cancer. *Oncotarget.* 2015; 6: 42632–50.

45. Monaco ME, Creighton CJ, Lee P, *et al.* Expression of long-chain fatty acyl-CoA synthetase 4 in breast and prostate cancers is associated with sex steroid hormone receptor negativity. *Transl Oncol.* 2010; 3: 91–8.

46. Wu X, Li Y, Wang J, *et al.* Long chain fatty acyl-CoA synthetase 4 is a biomarker for and mediator of hormone resistance in human breast cancer. *PloS One.* 2013; 8: e77060.